A drug called terazosin, which boosts energy production in brain cells, reduces seizures and prevents death in mice with the APOE4 gene variant, but has no effect on mice with the APOE3 gene, suggesting that energy deficits specifically linked to APOE4 can be targeted therapeutically.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether terazosin or other PGK1 activators consistently reduce seizure frequency or severity in human APOE4 carriers with epilepsy or Alzheimer’s disease across clinical trials.
A systematic review and meta-analysis of all published clinical trials testing PGK1 activators (e.g., terazosin) in APOE4-positive individuals with epilepsy or AD-related seizures, pooling data on seizure frequency, EEG biomarkers, ATP levels via MRS, and safety outcomes.
Whether terazosin reduces seizure frequency in APOE4 homozygous adults with mild cognitive impairment and subclinical epileptiform activity.
A double-blind, placebo-controlled trial of 120 adults aged 65–80 with APOE4/4 genotype and EEG-confirmed subclinical seizures, randomized to terazosin 1 mg/day or placebo for 24 weeks, with primary outcome being reduction in epileptiform discharges on 72-hour ambulatory EEG and secondary outcomes including hippocampal ATP via MRS and cognitive decline.
Whether long-term terazosin use in APOE4 carriers with hypertension is associated with lower incidence of unprovoked seizures compared to other antihypertensives.
A prospective cohort study of 10,000 APOE4 carriers aged 55–75 with hypertension, comparing seizure incidence over 10 years between those prescribed terazosin versus other antihypertensives (e.g., ACE inhibitors, calcium channel blockers), adjusting for age, sex, Aβ burden, and comorbidities.
Whether APOE4 carriers who developed seizures while on terazosin had higher baseline hippocampal ATP levels than those who did not.
A case-control study comparing 50 APOE4 carriers who developed seizures while on terazosin with 50 matched APOE4 carriers on terazosin who did not develop seizures, analyzing pre-treatment hippocampal ATP levels via MRS and PGK1 activity in stored blood samples.
Whether APOE4 carriers taking terazosin have higher hippocampal ATP levels on MRS than those not taking it.
A cross-sectional study of 80 APOE4 carriers aged 60–75, 40 on terazosin and 40 not, matched for age, sex, and hypertension severity, undergoing 3T MRS to measure hippocampal ATP and lactate levels, with blood tests for PGK1 activity.